RADNOR, Pa., March 11, 2024 /PRNewswire/-- NRx Pharmaceuticals, Inc. and its wholly owned subsidiary HOPE Therapeutics announced completion of a Memorandum of Understanding with Conversio Health and a strong, ongoing partnership with Nephron Pharmaceuticals to provide IV Ketamine to patients and clinics across the country, subject to board approval.  These are important steps to providing a full suite of ketamine options for customers across the country, and preparation for potential approval of HTX-100 by regulatory authorities worldwide. The Company has further entered into a business relationship with an organization that currently serves the business needs of more than 100 ketamine clinics nationwide. The Company has been given a target delivery date prior to the end of this month (March 2024) for initial stock of ketamine for sale to licensed end users. Sales are planned to commence once technical and logistical elements are finalized.  In contrast to NRx Pharmaceuticals, which is structured as a Biotechnology research and development company, HOPE Therapeutics is structured as a Specialty Pharmaceutical company that aims to supply a variety of therapeutic products to clinics that are treating suicidal depression and PTSD, including both traditional and digital therapeutics.